1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome
- PMID: 15089763
- DOI: 10.1111/j.0902-4441.2003.00210.x
1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome
Abstract
Purinergic P2X7 receptors are ligand-gated cation channels expressed on the cells of the immune and hemopoietic system which have been shown to mediate the ATP-induced apoptotic death of monocytes, macrophages and lymphocytes. A common single nucleotide polymorphism within the P2X7 gene has been described in exon 13 (1513A/C), the gene products encoding fully active and non-functional proteins. We genotyped the P2X7 1513A/C polymorphism using DNA from 111 patients with chronic lymphocytic leukemia (CLL) and 97 healthy controls using polymerase chain reaction (PCR) amplification followed by Hha1 restriction analysis. We found no significant difference in allele frequency between CLL patients and controls. Time periods from diagnosis to initiation of chemotherapy, a surrogate marker for disease progression, were not different in patients displaying the combined 1513A/C and C/C or the 1513A/A genotype (P = 0.97). Similar results were observed in a subgroup analysis of prognostically more favorable CD38-negative and ZAP-70-negative CLL patients. In conclusion, our data do not support a role of the P2X7 genotype as a prognostic marker in B-cell CLL.
Similar articles
-
Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia.Lancet. 2002 Dec 14;360(9349):1935-9. doi: 10.1016/S0140-6736(02)11917-9. Lancet. 2002. PMID: 12493261
-
P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12.Leukemia. 2003 Nov;17(11):2097-100. doi: 10.1038/sj.leu.2403125. Leukemia. 2003. PMID: 12931211
-
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.Leukemia. 2005 May;19(5):750-8. doi: 10.1038/sj.leu.2403707. Leukemia. 2005. PMID: 15759031
-
The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia.J Biol Regul Homeost Agents. 2004 Jul-Dec;18(3-4):340-6. J Biol Regul Homeost Agents. 2004. PMID: 15786702 Review.
-
CD38 as a prognostic marker in CLL.Hematology. 2005 Feb;10(1):39-46. doi: 10.1080/10245330400020470. Hematology. 2005. PMID: 16019444 Review.
Cited by
-
The hyposensitive N187D P2X7 mutant promotes malignant progression in nude mice.J Biol Chem. 2010 Nov 12;285(46):36179-87. doi: 10.1074/jbc.M110.128488. Epub 2010 Sep 13. J Biol Chem. 2010. PMID: 20837475 Free PMC article.
-
Predicted the P2RX7 rs3751143 polymorphism is associated with cancer risk: a meta-analysis and systematic review.Biosci Rep. 2021 Feb 26;41(2):BSR20193877. doi: 10.1042/BSR20193877. Biosci Rep. 2021. PMID: 33501930 Free PMC article.
-
Association between the rs3751143 polymorphism of P2RX7 gene and chronic lymphocytic leukemia: A meta-analysis.Purinergic Signal. 2020 Dec;16(4):479-484. doi: 10.1007/s11302-020-09737-8. Epub 2020 Oct 7. Purinergic Signal. 2020. PMID: 33026566 Free PMC article. Review.
-
Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms.Front Pharmacol. 2013 May 7;4:55. doi: 10.3389/fphar.2013.00055. eCollection 2013. Front Pharmacol. 2013. PMID: 23675347 Free PMC article.
-
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer.Front Immunol. 2015 Aug 7;6:402. doi: 10.3389/fimmu.2015.00402. eCollection 2015. Front Immunol. 2015. PMID: 26300886 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
